Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
143.31
287.01
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ALNY stock under the Base Case scenario is 167.29 USD. Compared to the current market price of 255.23 USD, Alnylam Pharmaceuticals Inc is Overvalued by 34%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Alnylam Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling ALNY based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Alnylam Pharmaceuticals Inc. is at the forefront of transforming the landscape of genetic medicine through its pioneering work in RNA interference (RNAi) technology. Founded in 2002, the company embarked on a bold mission to develop innovative therapies for rare and challenging diseases caused by genetic mutations. By leveraging the power of RNAi, Alnylam enables the silencing of specific disease-causing genes, offering a potential cure rather than just symptomatic relief. Their flagship products, like Onpattro and GIVLAARI, have already gained approval for treating debilitating conditions such as hereditary transthyretin-mediated amyloidosis and acute hepatic porphyria, making waves in the...
Alnylam Pharmaceuticals Inc. is at the forefront of transforming the landscape of genetic medicine through its pioneering work in RNA interference (RNAi) technology. Founded in 2002, the company embarked on a bold mission to develop innovative therapies for rare and challenging diseases caused by genetic mutations. By leveraging the power of RNAi, Alnylam enables the silencing of specific disease-causing genes, offering a potential cure rather than just symptomatic relief. Their flagship products, like Onpattro and GIVLAARI, have already gained approval for treating debilitating conditions such as hereditary transthyretin-mediated amyloidosis and acute hepatic porphyria, making waves in the biotechnology sector and establishing the company as a leader in genetic medicines.
Investors have taken note of Alnylam's unique position in a rapidly evolving market, propelled by its strong pipeline of therapies aimed at multiple diseases. With a robust clinical trial framework and strategic partnerships with major pharmaceutical players, Alnylam not only raises its profile but also enhances its growth potential. The company is on a path to deliver multiple additional product candidates and expand its therapeutic reach into areas like cardiometabolic and neurodegenerative diseases. For those looking to invest in a company that combines scientific innovation with robust market potential, Alnylam Pharmaceuticals represents a compelling narrative filled with promise and transformative possibilities in the realm of healthcare.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of therapies based on RNA interference (RNAi) technology. This innovative approach allows for the targeting of specific genes to treat genetic diseases. Below are the core business segments of Alnylam Pharmaceuticals:
-
Therapeutics Development:
- RNAi Therapeutics: The primary focus of Alnylam is to develop RNAi-based therapeutics, which can silence defective genes responsible for various diseases. The company has a pipeline of product candidates targeting rare genetic disorders, cardiovascular diseases, and liver-related conditions.
-
Commercial Products:
- Alnylam has successfully launched several RNAi therapeutics, such as Onpattro (patisiran) for hereditary transthyretin-mediated Amyloidosis (hATTR Amyloidosis) and Givlaari (givosiran) for acute hepatic porphyria. These products represent a crucial revenue stream for the company.
-
Research and Development (R&D):
- Significant investment in R&D is essential for Alnylam's strategy, allowing the company to expand its pipeline and explore new therapeutic areas. This includes preclinical and clinical trials for both the development of new drugs and the enhancement of existing therapies.
-
Collaborations and Partnerships:
- Alnylam engages in strategic collaborations with other pharmaceutical and biotechnology companies, academic institutions, and research organizations. These partnerships can include co-development agreements, licensing deals, and joint ventures, which enhance its research capabilities and market reach.
-
Platform Technology:
- The company is building a platform around its RNAi technology, which can be applied to a variety of therapeutic targets and disease areas. This versatile platform positions Alnylam to innovate continuously and adapt to emerging medical needs.
-
Global Market Expansion:
- As Alnylam seeks to expand its market presence, it focuses on global reach, ensuring access to its therapies across different regions. This segment involves navigating regulatory environments and establishing distribution channels in international markets.
By concentrating on these core business segments, Alnylam Pharmaceuticals aims to pioneer RNAi therapeutics and position itself as a leader in the biopharmaceutical industry focused on treating rare and genetic diseases.
Alnylam Pharmaceuticals Inc. has several unique competitive advantages that distinguish it from its rivals in the biopharmaceutical industry, particularly in the RNA interference (RNAi) therapeutics field. Here are some key points:
-
Pioneering Technology: Alnylam is a leader in the development of RNAi-based therapeutics, which can selectively silence disease-causing genes at the RNA level. This proprietary technology provides a unique approach to treating various genetic disorders.
-
Strong Intellectual Property Portfolio: Alnylam has built an extensive portfolio of patents and licenses related to RNAi technology. This strong intellectual property position not only protects its innovations but also creates barriers to entry for competitors.
-
Robust Pipeline: The company has a diverse and advanced pipeline of RNAi therapeutics, targeting a range of diseases, including rare genetic disorders and cardiovascular diseases. This broad pipeline increases the likelihood of multiple successful product launches in the future.
-
Partnerships and Collaborations: Alnylam has established strategic partnerships with larger pharmaceutical companies, such as Sanofi and Regeneron. These collaborations provide additional funding, resources, and distribution channels that enhance their research and development capabilities.
-
Clinical Development Expertise: The company has gained significant experience and expertise in conducting clinical trials for RNAi therapeutics. This experience helps to navigate regulatory pathways effectively and accelerates the time to market for new therapies.
-
Strong Market Position: As one of the first companies to bring RNAi therapeutics to market, Alnylam has established a strong brand reputation and market presence. This early mover advantage enables it to capture market share and recognition among healthcare providers and patients.
-
Focused Strategy on Rare Diseases: Alnylam focuses on developing treatments for rare, genetically defined diseases, which often have unmet needs. This targeted approach allows for high pricing potential and a loyal patient population, which can be less price-sensitive compared to broader indications.
-
Commitment to Innovation: The company continuously invests in research and development to refine its RNAi technology and explore new therapeutic applications. This commitment fosters a culture of innovation that can lead to breakthrough discoveries.
-
Regulatory Approvals and Commercial Success: Alnylam has already achieved FDA approvals for several products, demonstrating its capability to navigate regulatory hurdles effectively. Successful commercialization of its therapeutics adds to its competitive advantage and validates its technology platform.
-
Growing Awareness and Acceptance of RNAi: As the medical community becomes more aware of RNAi technology and its potential, Alnylam stands to benefit from being an established leader in this domain when compared to newer entrants.
These competitive advantages, when leveraged effectively, position Alnylam Pharmaceuticals as a key player in the biopharmaceutical industry with significant potential for growth and success.
Alnylam Pharmaceuticals Inc., as a leading company in the field of RNA interference (RNAi) therapies, faces several risks and challenges that could impact its operations and growth prospects in the near future. Here are some key considerations:
-
Regulatory Risks: The biotechnology sector, particularly companies developing novel therapies such as RNAi, is subject to rigorous regulatory scrutiny. Delays in obtaining regulatory approvals from agencies like the FDA for new drugs can hinder product launches and therefore revenue.
-
Clinical Trial Risks: The company is reliant on the successful results of clinical trials for its drug candidates. Failures or setbacks in clinical trials can adversely impact the company's stock price and market position.
-
Market Competition: The RNAi space is becoming increasingly competitive, with other companies potentially developing similar therapies. The ability to maintain a competitive edge through innovation and effective marketing will be crucial.
-
Intellectual Property Challenges: Protecting intellectual property rights is vital in the biotech industry. Alnylam may face challenges related to patent enforcement or infringement that could impact its market share and ability to monetize its discoveries.
-
Financial Risks: Like many biotech firms, Alnylam relies on a combination of equity funding, partnerships, and revenue from product sales. Economic downturns, changes in investor sentiment, or unsuccessful product launches could impact its financial stability.
-
Market Adoption and Commercialization: Even with successful clinical outcomes and regulatory approvals, a challenge exists in convincing healthcare providers and payers to adopt new therapies and provide them to patients. Building relationships and convincing stakeholders of the drug’s value is critical.
-
Supply Chain and Manufacturing Issues: Disruptions in the supply chain, whether due to geopolitical events, natural disasters, or economic factors, could impact Alnylam's ability to produce and distribute its therapies.
-
Price Pressure and Reimbursement Challenges: With increasing scrutiny on drug pricing from governments and payers, Alnylam may face pressure to demonstrate the value of its therapies. Additionally, achieving favorable reimbursement terms can be challenging.
-
Talent Acquisition and Retention: Finding and retaining qualified talent in the highly specialized field of biotechnology can be challenging. A failure to attract the right talent can stifle innovation.
-
Public Perception and Acceptance: As with any new technology, there may be public skepticism about RNAi technologies. Misunderstandings or negative perceptions can influence adoption rates among physicians and patients.
Navigating these risks and challenges requires strategic foresight, careful risk management, and a commitment to compliance and ethical practices in order to sustain growth and maintain the company’s competitive position in the biotechnology landscape.
Revenue & Expenses Breakdown
Alnylam Pharmaceuticals Inc
Balance Sheet Decomposition
Alnylam Pharmaceuticals Inc
Current Assets | 3.2B |
Cash & Short-Term Investments | 2.6B |
Receivables | 309.5m |
Other Current Assets | 238.7m |
Non-Current Assets | 836.8m |
PP&E | 715.5m |
Other Non-Current Assets | 121.3m |
Current Liabilities | 1.1B |
Accounts Payable | 74m |
Accrued Liabilities | 850.3m |
Other Current Liabilities | 131m |
Non-Current Liabilities | 3B |
Long-Term Debt | 1B |
Other Non-Current Liabilities | 1.9B |
Earnings Waterfall
Alnylam Pharmaceuticals Inc
Revenue
|
2.3B
USD
|
Cost of Revenue
|
-304.8m
USD
|
Gross Profit
|
2B
USD
|
Operating Expenses
|
-1.9B
USD
|
Operating Income
|
102.7m
USD
|
Other Expenses
|
-175.6m
USD
|
Net Income
|
-72.9m
USD
|
Free Cash Flow Analysis
Alnylam Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
In Q2 2024, Alnylam Pharmaceuticals achieved a 34% year-over-year increase in global net product revenues, reaching $410 million, driven by a 37% rise in the transthyretin (TTR) business. The company raised its full-year revenue guidance by 11% at the midpoint, anticipating net product revenues between $1.575 billion and $1.65 billion. Key highlights include positive HELIOS-B Phase III results for vutrisiran, showing a 35%-36% mortality benefit and potential as a new standard for ATTR cardiomyopathy, pending regulatory approval. Their pipeline remains strong with plans for 15 new INDs by end of 2025, setting the stage for sustained growth and innovation .
What is Earnings Call?
ALNY Profitability Score
Profitability Due Diligence
Alnylam Pharmaceuticals Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Alnylam Pharmaceuticals Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
ALNY Solvency Score
Solvency Due Diligence
Alnylam Pharmaceuticals Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Alnylam Pharmaceuticals Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALNY Price Targets Summary
Alnylam Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for ALNY is 291.87 USD with a low forecast of 162.11 USD and a high forecast of 420 USD.
Shareholder Yield
Current shareholder yield for ALNY is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
ALNY Price
Alnylam Pharmaceuticals Inc
Average Annual Return | 30.17% |
Standard Deviation of Annual Returns | 13.13% |
Max Drawdown | -15% |
Market Capitalization | 32.7B USD |
Shares Outstanding | 126 000 000 |
Percentage of Shares Shorted | 4.04% |
Ownership
ALNY Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1,665 full-time employees. The company went IPO on 2004-05-28. The company is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STArs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. Leqvio is used for the treatment of adults with hypercholesterolemia.
Contact
IPO
Employees
Officers
The intrinsic value of one ALNY stock under the Base Case scenario is 167.29 USD.
Compared to the current market price of 255.23 USD, Alnylam Pharmaceuticals Inc is Overvalued by 34%.